Verrica Pharma announces positive preliminary top-line results for VP-315
Shares of American dermatology company Verrica Pharmaceuticals (Nasdaq: VRCA) had a roller-coaster start to the day after announcing what it called positive trial results, leaping 23% pre-market but plunging 27.8% to $3.80 by late morning trading when it also announced financials.
Verrica released preliminary positive results from Part 2 of its Phase II clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma (BCC), licensed from Norwegian firm Lytix Biopharma.
The study investigated drug candidate in BCC patients and shows impressively an: 86% overall reduction of tumor size; 51% complete clearance rate of basal cell carcinomas (total removal); and 1% average reduction in tumor size of patients with residual carcinomas
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze